ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0734

Insights into Readmissions of ANCA-Vasculitis Patients: A Nationwide Analysis

Faria Sami1 and Rohan Gajjar2, 1University of Alabama, Chicago, IL, 2John H. Stroger Hospital of Cook County, Chicago, IL

Meeting: ACR Convergence 2024

Keywords: ANCA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: ANCA vasculitis is an immune-medicated inflammation affecting small-medium vessels and manifesting with a wide spectrum of clinical manifestations most commonly involving the lungs and kidneys. There is a paucity of data on readmissions of ANCA vasculitis patients. We wish to study the hospital readmission rates, common causes, and predictors of readmissions among patients with ANCA-associated vasculitis.

Methods: We used the National Readmission Database from  2016 to 2020 to extract data and identify all index hospitalizations with ANCA vasculitis as the principal diagnosis by using the ICD-10 CM codes. We used STATA 17.0 to analyze the most common specific principal diagnoses of ANCA vasculitis patients’ 90-day readmissions. Multivariate and univariate logistic and linear regression analyses were done to evaluate the predictors and adjust for potential confounders.

Results: A total of 34,022 adult patients with ANCA vasculitis were identified, out of which, 32,326 were discharged alive. Within 90 days of discharge, 9,765 (30.2%) were readmitted. Readmissions led to an additional 6.4 days mean length of hospital stay and a mean total hospital charge of $75,834. Those readmitted had higher proportions of older patients aged >65 years, belonged to a lower socioeconomic class with a mean household income quartile below the median, were insured with Medicare/Medicaid, and the majority had a higher burden of comorbidities with mean Elixhauser comorbidity index score >3, but were similar in gender and other hospital characteristics. The top five causes of readmissions were sepsis (10.1%), acute renal failure (ARF) (3.5%), pneumonia (3.3%), hypertensive heart failure with chronic kidney disease (CKD) (4.8%), and ANCA vasculitis (4.2%). Figure-1 shows the forest plot of a multivariate analysis of independent predictors of readmissions.

Conclusion: Within 90 days, 30.2% of ANCA vasculitis patients were readmitted, primarily due to sepsis, ARF, hypertensive heart failure with CKD, ANCA vasculitis, and pneumonia. Readmissions were from older age group, lower socioeconomic status, and higher comorbidity burdens. Hemodialysis, hypertension, COPD, CAD, cancer, cirrhosis, anemia and transfusions, shorter length of stay, leaving against medical advice, CHF, diabetes, higher Elixhauser comorbidity score, transfer to rehab/nursing center, and lack of insurance were predictors of readmissions. This underscores the need for better comorbidity management and post-discharge care for ANCA vasculitis patients.

Supporting image 1

Forest plot representing predictors of 90-day readmission in ANCA vasculitis patients


Disclosures: F. Sami: None; R. Gajjar: None.

To cite this abstract in AMA style:

Sami F, Gajjar R. Insights into Readmissions of ANCA-Vasculitis Patients: A Nationwide Analysis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/insights-into-readmissions-of-anca-vasculitis-patients-a-nationwide-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/insights-into-readmissions-of-anca-vasculitis-patients-a-nationwide-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology